Is obesity an advantage in patients with colorectal cancer?

Pashtoon Murtaza Kasi, S. Yousuf Zafar, Axel F Grothey

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Obesity/higher BMI appears to be important determinants in the development of colon cancer as well as in predicting outcomes in the adjuvant setting in these patients. These associations seem to be stronger for men and tend to be J-shaped, with worse outcomes in both lower and upper BMI categories than in the middle categories. How this factors in the metastatic setting is less clear. A recent pooled analysis of patients with metastatic colorectal cancer receiving bevacizumab in the first-line setting observed that patients with the lowest BMI had the lowest median overall survival. An incremental BMI increase of 5 kg/m2 led to actually a decrease in the risk of death (hazard ratio, 0.911 [95% CI, 0.879-0.944]). The observed association does not necessarily mean that obesity is an advantage for patients with metastatic colorectal cancer. More likely, it is conceivable that, in patients with metastatic colorectal cancer with a lower BMI, the effects of cancer-related cachexia may be more deleterious than the potential adverse events related to a higher BMI. In patients already diagnosed with metastatic disease, studying how body weight affects tumor biology and treatment-related decisions are important considerations.

Original languageEnglish (US)
Pages (from-to)1339-1342
Number of pages4
JournalExpert Review of Gastroenterology and Hepatology
Volume9
Issue number11
DOIs
StatePublished - Nov 2 2015

Fingerprint

Colorectal Neoplasms
Obesity
Cachexia
Evoked Potentials
Colonic Neoplasms
Neoplasms
Body Weight
Survival
Therapeutics

Keywords

  • bevacizumab
  • biologics
  • BMI
  • body mass index
  • inflammation
  • leptin
  • metastatic colorectal cancer
  • obesity
  • vascular endothelial growth factor
  • visceral obesity

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Is obesity an advantage in patients with colorectal cancer? / Kasi, Pashtoon Murtaza; Zafar, S. Yousuf; Grothey, Axel F.

In: Expert Review of Gastroenterology and Hepatology, Vol. 9, No. 11, 02.11.2015, p. 1339-1342.

Research output: Contribution to journalArticle

Kasi, Pashtoon Murtaza ; Zafar, S. Yousuf ; Grothey, Axel F. / Is obesity an advantage in patients with colorectal cancer?. In: Expert Review of Gastroenterology and Hepatology. 2015 ; Vol. 9, No. 11. pp. 1339-1342.
@article{674c1f3fbf384aeea9f5bd74f83a8345,
title = "Is obesity an advantage in patients with colorectal cancer?",
abstract = "Obesity/higher BMI appears to be important determinants in the development of colon cancer as well as in predicting outcomes in the adjuvant setting in these patients. These associations seem to be stronger for men and tend to be J-shaped, with worse outcomes in both lower and upper BMI categories than in the middle categories. How this factors in the metastatic setting is less clear. A recent pooled analysis of patients with metastatic colorectal cancer receiving bevacizumab in the first-line setting observed that patients with the lowest BMI had the lowest median overall survival. An incremental BMI increase of 5 kg/m2 led to actually a decrease in the risk of death (hazard ratio, 0.911 [95{\%} CI, 0.879-0.944]). The observed association does not necessarily mean that obesity is an advantage for patients with metastatic colorectal cancer. More likely, it is conceivable that, in patients with metastatic colorectal cancer with a lower BMI, the effects of cancer-related cachexia may be more deleterious than the potential adverse events related to a higher BMI. In patients already diagnosed with metastatic disease, studying how body weight affects tumor biology and treatment-related decisions are important considerations.",
keywords = "bevacizumab, biologics, BMI, body mass index, inflammation, leptin, metastatic colorectal cancer, obesity, vascular endothelial growth factor, visceral obesity",
author = "Kasi, {Pashtoon Murtaza} and Zafar, {S. Yousuf} and Grothey, {Axel F}",
year = "2015",
month = "11",
day = "2",
doi = "10.1586/17474124.2015.1089170",
language = "English (US)",
volume = "9",
pages = "1339--1342",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Is obesity an advantage in patients with colorectal cancer?

AU - Kasi, Pashtoon Murtaza

AU - Zafar, S. Yousuf

AU - Grothey, Axel F

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Obesity/higher BMI appears to be important determinants in the development of colon cancer as well as in predicting outcomes in the adjuvant setting in these patients. These associations seem to be stronger for men and tend to be J-shaped, with worse outcomes in both lower and upper BMI categories than in the middle categories. How this factors in the metastatic setting is less clear. A recent pooled analysis of patients with metastatic colorectal cancer receiving bevacizumab in the first-line setting observed that patients with the lowest BMI had the lowest median overall survival. An incremental BMI increase of 5 kg/m2 led to actually a decrease in the risk of death (hazard ratio, 0.911 [95% CI, 0.879-0.944]). The observed association does not necessarily mean that obesity is an advantage for patients with metastatic colorectal cancer. More likely, it is conceivable that, in patients with metastatic colorectal cancer with a lower BMI, the effects of cancer-related cachexia may be more deleterious than the potential adverse events related to a higher BMI. In patients already diagnosed with metastatic disease, studying how body weight affects tumor biology and treatment-related decisions are important considerations.

AB - Obesity/higher BMI appears to be important determinants in the development of colon cancer as well as in predicting outcomes in the adjuvant setting in these patients. These associations seem to be stronger for men and tend to be J-shaped, with worse outcomes in both lower and upper BMI categories than in the middle categories. How this factors in the metastatic setting is less clear. A recent pooled analysis of patients with metastatic colorectal cancer receiving bevacizumab in the first-line setting observed that patients with the lowest BMI had the lowest median overall survival. An incremental BMI increase of 5 kg/m2 led to actually a decrease in the risk of death (hazard ratio, 0.911 [95% CI, 0.879-0.944]). The observed association does not necessarily mean that obesity is an advantage for patients with metastatic colorectal cancer. More likely, it is conceivable that, in patients with metastatic colorectal cancer with a lower BMI, the effects of cancer-related cachexia may be more deleterious than the potential adverse events related to a higher BMI. In patients already diagnosed with metastatic disease, studying how body weight affects tumor biology and treatment-related decisions are important considerations.

KW - bevacizumab

KW - biologics

KW - BMI

KW - body mass index

KW - inflammation

KW - leptin

KW - metastatic colorectal cancer

KW - obesity

KW - vascular endothelial growth factor

KW - visceral obesity

UR - http://www.scopus.com/inward/record.url?scp=84947129814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947129814&partnerID=8YFLogxK

U2 - 10.1586/17474124.2015.1089170

DO - 10.1586/17474124.2015.1089170

M3 - Article

C2 - 26366838

AN - SCOPUS:84947129814

VL - 9

SP - 1339

EP - 1342

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 11

ER -